Therapy
132 tracked therapy entities, ordered by how much was published about each in the last 30 days. 322 papers across 107 of them.
- Cisplatin 15 papers
- Glucagon-like peptide-1 receptor agonist 10 papers
- Bevacizumab 9 papers
- Paclitaxel 9 papers
- Doxorubicin 8 papers
- Gemcitabine 7 papers
- Radiation therapy 7 papers
- Capecitabine 6 papers
- Combination therapy 6 papers
- Monoclonal antibody 6 papers
- Nivolumab 6 papers
- Atezolizumab 5 papers
- Atorvastatin 5 papers
- Carboplatin 5 papers
- Durvalumab 5 papers
- Immunotherapy 5 papers
- Influenza vaccine 5 papers
- Platinum 5 papers
- Semaglutide 5 papers
- Sodium glucose cotransporter-2 (SGLT2) inhibitors 5 papers
- Sorafenib 5 papers
- Upadacitinib 5 papers
- Vaccination 5 papers
- Anti-PD-1 therapy 4 papers
- Dexamethasone 4 papers
- Fluorouracil 4 papers
- HPV vaccine 4 papers
- Lenvatinib 4 papers
- Rituximab 4 papers
- RNA vaccine 4 papers
- Temozolomide 4 papers
- Trastuzumab 4 papers
- Anti-PD-L1 3 papers
- Checkpoint inhibitor 3 papers
- Gene therapy 3 papers
- Lenalidomide 3 papers
- Melatonin 3 papers
- Methotrexate 3 papers
- Olaparib 3 papers
- Oxaliplatin 3 papers
- Pembrolizumab 3 papers
- Platelet-rich plasma 3 papers
- Rivaroxaban 3 papers
- Simvastatin 3 papers
- Statin 3 papers
- Tirzepatide 3 papers
- Vitamin D 3 papers
- Aflibercept 2 papers
- Alectinib 2 papers
- Antibody-drug conjugate 2 papers
- Aspirin 2 papers
- Bacillus Calmette-Guérin 2 papers
- CAR-T cells 2 papers
- Ciprofloxacin 2 papers
- COVID-19 vaccine 2 papers
- Cyclophosphamide 2 papers
- Dapagliflozin 2 papers
- Dasatinib 2 papers
- Docetaxel 2 papers
- Doxycycline 2 papers
- Dupilumab 2 papers
- Enfortumab vedotin 2 papers
- Fenofibrate 2 papers
- Finerenone 2 papers
- Glucagon-like peptide-1 agonist 2 papers
- Ibuprofen 2 papers
- Infliximab 2 papers
- Janus kinase inhibitors 2 papers
- Levodopa 2 papers
- Meropenem 2 papers
- Metformin 2 papers
- Ocrelizumab 2 papers
- Pioglitazone 2 papers
- Proton therapy 2 papers
- Sirolimus 2 papers
- Small molecule inhibitors 2 papers
- Taxane 2 papers
- Tislelizumab 2 papers
- Venetoclax 2 papers
- Abemaciclib 1 paper
- Adalimumab 1 paper
- Amphotericin B 1 paper
- Belimumab 1 paper
- Bortezomib 1 paper
- Cabozantinib 1 paper
- Celastrol 1 paper
- Celecoxib 1 paper
- Cetuximab 1 paper
- Cyclin-dependent kinase 4/6 inhibitors 1 paper
- Dexmedetomidine 1 paper
- Dolutegravir 1 paper
- Empagliflozin 1 paper
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors 1 paper
- Gefitinib 1 paper
- Glucocorticoid 1 paper
- Ibrutinib 1 paper
- Ipilimumab 1 paper
- Liraglutide 1 paper
- Niraparib 1 paper
- Nirsevimab 1 paper
- Osimertinib 1 paper
- Palbociclib 1 paper
- Photobiomodulation 1 paper
- Photothermal therapy 1 paper
- Rutin 1 paper
- Tyrosine-kinase inhibitor 1 paper
- Ustekinumab 1 paper
- [177Lu]Lu-PSMA-617
- Acarbose
- Amoxicillin
- Azithromycin
- Caelyx
- Calcineurin inhibitor
- Carbamazepine
- Ceftazidime-avibactam
- Cisplatin/fluorouracil
- Electroacupuncture
- Erlotinib
- Immunization
- Insulin Therapy
- Intravitreal rituximab
- Mesalazine
- Neoadjuvant or adjuvant chemotherapy
- Nirmatrelvir/ritonavir
- PARP inhibitor
- PD-1/PD-L1 blockade
- Quadrivalent HPV vaccination
- Quercetin hydrogel
- Ruxolitinib
- Tofacitinib
- Trametinib
- Vancomycin